Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q7L1T6

UPID:
NB5R4_HUMAN

ALTERNATIVE NAMES:
Flavohemoprotein b5/b5R; N-terminal cytochrome b5 and cytochrome b5 oxidoreductase domain-containing protein; cb5/cb5R

ALTERNATIVE UPACC:
Q7L1T6; B1AEM2; Q5TGI9; Q9NUE4; Q9UHI9

BACKGROUND:
The enzyme Cytochrome b5 reductase 4, known alternatively as N-terminal cytochrome b5 and cytochrome b5 oxidoreductase domain-containing protein, is key in the endoplasmic reticulum stress response. It protects pancreatic beta-cells against oxidant stress, potentially by preventing excessive reactive oxygen species (ROS) buildup. It has a broad substrate reduction capability, including cytochrome c, ferricyanide, and methemoglobin.

THERAPEUTIC SIGNIFICANCE:
Exploring the function of Cytochrome b5 reductase 4 offers a promising avenue for identifying novel therapeutic approaches. Its essential role in defending against oxidative stress underscores its value as a therapeutic target to boost cell survival under stress conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.